Marc Wilson
Finanzdirektor/CFO bei CRINETICS PHARMACEUTICALS, INC.
Vermögen: 5 Mio $ am 30.04.2024
Aktive Positionen von Marc Wilson
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
CRINETICS PHARMACEUTICALS, INC. | Finanzdirektor/CFO | 01.01.2018 | - |
Investor Relations Kontakt | 01.01.2018 | - |
Karriereverlauf von Marc Wilson
Ehemalige bekannte Positionen von Marc Wilson
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
CIDARA THERAPEUTICS, INC. | Comptroller/Controller/Auditor | 01.09.2014 | 03.01.2018 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Comptroller/Controller/Auditor | 01.01.2010 | 01.01.2014 |
Ausbildung von Marc Wilson
College of the Holy Cross (Massachusetts) | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 5 |
Operativ
Comptroller/Controller/Auditor | 2 |
Director of Finance/CFO | 1 |
Investor Relations Contact | 1 |
Sektoral
Health Technology | 4 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
CIDARA THERAPEUTICS, INC. | Health Technology |
CRINETICS PHARMACEUTICALS, INC. | Health Technology |
Private Unternehmen | 1 |
---|---|
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Health Technology |
- Börse
- Insiders
- Marc Wilson
- Erfahrung